Recursion Pharma RXRX shares have plunged 37.1% in the past month compared with the industry’s 1.4% decline. The company has also underperformed in the sector and the S&P 500 during the same time ...

Ascendis Pharma A/S (ASND) shares rallied 10.4% in the last trading session to close at $168.84. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

Vincerx Pharma shares jumped Tuesday morning after the company said that it has entered into an agreement to combine with privately held AI computing infrastructure company Global Digital Holdings.

During afternoon trading, there was significant selling pressure on Shukra Pharmaceuticals stock, which had a market value of Rs 1.08KCr. As a result, the stock was put at a 2% lower circuit limit of ...

Fear, uncertainty, and doubt have become the norm in early 2025 with rising stock market volatility. David Jagielski (Eli Lilly): A top pharma stock that I wouldn't hesitate to buy right now and ...

Explore Zentalis Pharma stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for ZNTL. FDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies ...

Laidlaw initiated coverage on shares of Nuvectis Pharma (NASDAQ:NVCT – Free Report) in a report released on Monday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $19.00 price ...

Novo Nordisk is launching a new direct-to-patient online pharmacy called NovoCare, which will offer Wegovy at a discounted price of $499 per month, less than half of its listed price. This offer ...

Checkpoint Therapeutics is being acquired by Sun Pharmaceutical for $4.10 per share. Learn why CKPT stockholders could earn ...

Hookipa Pharma (NASDAQ:HOOK – Get Free Report) is projected to issue its quarterly earnings data before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of ...

Sun Pharma is a top-ranked Indian pharmaceutical firm. The company’s stock has been continuously in the news lately for ...